TY - JOUR T1 - Raloxifene reduced vertebral fractures and breast cancer regardless of prior hormone therapy use in women JF - Evidence Based Medicine JO - Evid Based Med SP - 84 LP - 84 DO - 10.1136/ebm.10.3.84 VL - 10 IS - 3 A2 - , Y1 - 2005/06/01 UR - http://ebm.bmj.com/content/10/3/84.abstract N2 - Johnell O, Cauley JA, Kulkarni PM, et al. Raloxifene reduces risk of vertebral fractures and breast cancer in postmenopausal women regardless of prior hormone therapy. J Fam Pract 2004;53:789–96.OpenUrlPubMedWeb of Science 
 
 Q In postmenopausal women with osteoporosis, does previous hormone therapy (HT) influence the effect of raloxifene on the risk of vertebral fractures and breast cancer? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Gynaecology ★★★★★★☆ Oncology ★★★★★★☆ Endocrine ★★★★★★☆ Design: randomised placebo controlled trial (the Multiple Outcomes of Raloxifene Evaluation [MORE] trial). Allocation: {concealed*}†. Blinding: blinded {patients, healthcare providers, and outcome assessors}†.* Follow up period: 4 years. Setting: {180 clinical centres in 25 countries}†. Patients: 7705 postmenopausal women ⩽80 years of age (mean age 67 y) with osteoporosis. 7682 women (99.7%) reported HT status; 2235 women (29.1%) had used HT previously. Exclusion criteria included other bone diseases and history of breast or endometrial cancer Intervention: among women with … ER -